SEARCH
You are in browse mode. You must login to use MEMORY

   Log in to start


From course:

CNS Pharmacology

» Start this Course
(Practice similar questions for free)
Question:

H. Levetiracetam

Author: Suzuki



Answer:

Levetiracetam is approved for adjunct therapy of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children. The exact mechanism of anticonvulsant action is unknown. It demonstrates high affinity for a synaptic vesicle protein (SV2A). The drug is well absorbed orally and excreted in urine mostly (66 percent) unchanged. The drug does not interact with CYP or UGT metabolism systems. Side effects most often reported include dizziness, sleep disturbances, headache, and weakness.


0 / 5  (0 ratings)

1 answer(s) in total

Author

Suzuki
Suzuki